What You Should Know About Gilead's Sovaldi And Johnson & Johnson's Olysio
Todd Campbell, The Motley Fool - Motley Fool - Thu Apr 24, 5:30PM CDT
Over the past five years, few drugs have been as highly anticipated as Gilead's Sovaldi, a new-generation oral treatment for hepatitis C infection. Sovaldi won FDA approval in December, and despite only being available for a few weeks, Sovaldi...
Final Glance: Biotechnology companies
AP - Thu Apr 24, 5:04PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
Alexion Posts Strong Earnings in Q1 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 24, 4:00PM CDT
Alexion (ALXN) handsomely beat the Zacks Consensus Estimate in the first quarter.
Celgene Beats on First-Quarter Earnings: What's Next?
George Budwell, The Motley Fool - Motley Fool - Thu Apr 24, 1:30PM CDT
Source: www.fiercepharma.com. Celgene Corporation is the second-largest component of the iShares Nasdaq Biotech Index . As such, its 14% plus nosedive year to date has undoubtedly played a role in driving this key biotech index lower for...
Midday Glance: Biotechnology companies
AP - Thu Apr 24, 12:28PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
Early Glance: Biotechnology companies
AP - Thu Apr 24, 9:32AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are down at 10 a.m.:
Stock Market News for April 24, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Thu Apr 24, 9:06AM CDT
Benchmarks ended lower on Wednesday following disappointing corporate results and economic data
Ambit Biosciences Slumps: AMBI Falls 7.1% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 24, 7:49AM CDT
Ambit Biosciences saw a big move last session, as the company’s shares fell by over 7% on the day
Why Gilead Sciences (GILD) Isn't Done Growing Earnings Yet - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 24, 7:47AM CDT
Gilead Sciences is well-positioned for future earnings growth
Earnings from Gilead and Amgen Put These ETFs in Focus - ETF News And Commentary
Zacks Equity Research - Zacks Investment Research - Thu Apr 24, 7:00AM CDT
Solid results from Gilead, but poor results from Amgen, look to have a big impact on these health care ETFs.
Strategists Dismiss Nasdaq, Nikkei Wobbles
at The Street - Thu Apr 24, 5:00AM CDT
Wobbles in the Nasdaq this year are not a 'canary in the coalmine' for a broader pullback in markets, strategists say, pointing to the concentrated nature of weakness in tech and biotech stocks.
Should You Invest in Gilead Sciences, Inc. Today?
Mark Reeth, The Motley Fool - Motley Fool - Wed Apr 23, 5:30PM CDT
Shares of biopharma giant Gilead Sciences were up today after it announced a strong quarter, which included revenue doubling to $5 billion and earnings per share tripling from $0.43 to $1.33. Most of the company's strength this quarter came...
Most active Nasdaq-traded stocks
AP - Wed Apr 23, 5:04PM CDT
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:
AbbVie Files for HCV Combination Therapy in U.S. - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 23, 4:21PM CDT
AbbVie submitted a NDA to the FDA for its investigational hepatitis C virus infection therapy.
Stocks Slip on Deep Drop in U.S. Home Sales
at The Street - Wed Apr 23, 3:24PM CDT
Major U.S. stock markets slide Wednesday amid poor Chinese economic data and a 14.5% month-over-month drop in U.S. new-home sales.
Earnings Roundup: What You Need to Know About Gilead's Blockbuster Quarter
Todd Campbell, The Motley Fool - Motley Fool - Wed Apr 23, 1:30PM CDT
Gilead's investors were wondering how long it would take for the company's newly launched hepatitis C drug Sovaldi to become a blockbuster; investors found out this week that the answer was less than one quarter. Sovaldi's sales totaled $2.3...
Stocks Trading Lower In Afternoon Action
at Investor's Business Daily - Wed Apr 23, 12:40PM CDT
Stocks were trading lower in early afternoon action Wednesday as the season for earnings reports hit full stride. The Nasdaq was down 0.6%, while the S&P 500 and the Dow Jones industrial average were off less than 0.1% each. Volume was running lower...
Biogen's Q1 Earnings Soar Y/Y on Tecfidera Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 23, 12:40PM CDT
Although Biogen (BIIB) missed earnings estimates, revenues surpassed expectations easily. The company also raised its guidance.